Compare Stocks

First Cobalt Corp. acquires and explores for resource properties in the United States and Canada. The company primarily explores for cobalt and silver deposits. Its flagship project is the Iron Creek cobalt project, which covers an area of approximately 2,600 acres located in Lemhi County, Idaho. The company was formerly known as Aurgent Resource Corp. and changed its name to First Cobalt Corp. in September 2016. First Cobalt Corp. was incorporated in 2011 and is headquartered in Toronto, Canada.

Golden Predator Mining Corp., an exploration stage company, engages in the acquisition and exploration of mineral properties in Canada. The company explores for gold, silver, copper, lead, and zinc properties. Its principal property is the Brewery Creek project covering an area of 180 square kilometers located in northwestern Yukon. The company was formerly known as Northern Tiger Resources Inc. and changed its name to Golden Predator Mining Corp. in April 2014. Golden Predator Mining Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Solitario Resources Corp., an exploration stage company, engages in the acquisition and exploration of precious metal, zinc, and other base metal properties in North and South America. The company holds 50% interest in the Lik zinc-lead-silver property located in Northwest Alaska; 39% interest in the Florida Canyon zinc project located in northern Peru; and 85% interest in the Chambara exploration project located in Peru. It also holds interest in the Golden Crest project located in western South Dakota, Lawrence County. The company was formerly known as Solitario Zinc Corp. and changed its name to Solitario Resources Corp. in July 2023. Solitario Resources Corp. was incorporated in 1984 and is based in Wheat Ridge, Colorado.